Browse the evidence

Tirzepatide treatment significantly reduced the 10-year predicted risk of developing type 2 diabetes compared with placebo in participants with obesity or overweight.

Practitioners can consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Excess body weight is a significant risk factor for breast cancer and increases the risk of therapy-related morbidity, recurrence, and breast cancer-related mortality.

Healthcare providers should prioritize weight management in breast cancer patients and survivors.

An active perioperative GLP-1 RA prescription in patients with diabetes was associated with a significantly reduced risk of 30-day readmission (RR: 0.883; P = 0.028).

Practitioners may consider GLP-1 RA prescriptions to reduce readmission rates in diabetic surgical patients.

The MR group experienced a significantly higher increase in lean mass, strength, and power than the PR group after 6 weeks of resistance training.

Incorporating high-protein dairy milk post-exercise and pre-sleep may enhance muscle gains and strength in young males undergoing resistance training.

Serum levels of IGF-1, growth hormone, testosterone, and follistatin increased, while cortisol and myostatin decreased in the MR group compared to the PR group.

Monitoring hormonal responses may provide insights into the effectiveness of dietary interventions in resistance training.

Strategic ingestion of high-protein dairy milk augmented lean mass, strength, power, and altered serum concentrations of skeletal muscle regulatory markers.

Implementing high-protein dairy milk in post-exercise and pre-sleep nutrition can enhance training outcomes.

The percentage of weight loss as fat-free mass (%FFML) using GLP-1RA-based agents was between 20% and 40%.

Practitioners can expect that GLP-1RA treatments may lead to significant fat-free mass loss.

AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks.

Practitioners can consider AOMs as effective long-term options for weight management.

Medication options are available to treat obesity, which can help reduce appetite and/or reduce caloric intake.

Practitioners can consider pharmacological treatments to assist patients in managing obesity.

GLP-1 receptor agonists have been successfully used in the treatment of obesity and type 2 diabetes.

GLP-1 receptor agonists can be considered as a treatment option for patients with obesity and T2DM.

Postexercise whole egg ingestion increases knee extension and handgrip strength, testosterone, and reduces body fat percentage compared with postexercise egg white ingestion.

Practitioners may consider recommending whole egg consumption post-exercise for improved strength and body composition.

There was a significant group × time interaction for body fat percentage, serum testosterone, knee extension, and handgrip strength with greater improvements observed in the whole egg group.

The results suggest that whole egg consumption may be more beneficial for strength and body composition improvements during resistance training.

Tirzepatide has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective GLP-1 RAs.

Tirzepatide may be a more effective option for managing HbA1c and body weight in patients compared to existing therapies.

Semaglutide therapy resulted in a 62.9% resolution of MASH without worsening of fibrosis compared to 34.3% in placebo (p <0.001).

Clinicians can consider semaglutide as an effective treatment option for MASH with moderate-to-advanced fibrosis.

Obesity increases the risk for Type 2 diabetes, hypertension, and cardiovascular disease.

Healthcare providers should prioritize weight management in patients with cardiovascular disease.

Recent guidelines prioritize pharmacologic interventions for weight management in Type 2 diabetes.

Healthcare providers should consider pharmacologic options for weight management in diabetic patients.

The oral formulation of semaglutide reduced AF incidence by 52%.

The oral formulation of semaglutide may be particularly effective in reducing AF risk.

Prandial insulin doses in the treatment of people with diabetes should take into account the pre-meal glycemia as well as the size and composition of meals.

Practitioners should consider both glycemia and meal composition when determining insulin doses.

Semaglutide use is effective in patients with IBD and obesity, resulting in a mean weight loss of over 5%.

Clinicians can consider semaglutide as a viable weight loss option for patients with IBD and obesity.

Semaglutide is associated with weight loss in adults.

Practitioners can consider semaglutide as a treatment option for weight loss in adults with type 2 diabetes or obesity.

Semaglutide improves control of diabetes in adults.

Practitioners can utilize semaglutide to enhance diabetes management in adults.

GLP-1 receptor agonists (GLP-1 RA) are a safe and effective treatment for weight regain and insufficient weight loss after metabolic bariatric surgery.

Practitioners can consider GLP-1 RA as a viable option for patients struggling with weight management post-surgery.

Weekly semaglutide leads to significantly greater weight loss compared to daily liraglutide.

Clinicians may prefer semaglutide over liraglutide for enhanced weight loss outcomes.

Women on hormone therapy (HT) had a higher total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months compared to women not on HT.

Practitioners may consider hormone therapy as a factor in weight loss strategies for postmenopausal women.